3535-35-1 Usage
General Description
4-ISOBUTOXY-3-METHOXY-BENZOIC ACID is a chemical compound with the molecular formula C12H16O4. It is a derivative of benzoic acid, containing both an isobutoxy and a methoxy group on the benzene ring. 4-ISOBUTOXY-3-METHOXY-BENZOIC ACID is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also utilized in the production of polymers and other industrial chemicals. 4-ISOBUTOXY-3-METHOXY-BENZOIC ACID has been found to have anti-inflammatory and analgesic properties, making it a potential candidate for therapeutic applications. Overall, this compound has a wide range of industrial and medicinal uses due to its versatile chemical properties.
Check Digit Verification of cas no
The CAS Registry Mumber 3535-35-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,5,3 and 5 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 3535-35:
(6*3)+(5*5)+(4*3)+(3*5)+(2*3)+(1*5)=81
81 % 10 = 1
So 3535-35-1 is a valid CAS Registry Number.
InChI:InChI=1/C12H16O4/c1-8(2)7-16-10-5-4-9(12(13)14)6-11(10)15-3/h4-6,8H,7H2,1-3H3,(H,13,14)
3535-35-1Relevant articles and documents
Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu7 Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962)
Reed, Carson W.,Yohn, Samantha E.,Washecheck, Jordan P.,Roenfanz, Hanna F.,Quitalig, Marc C.,Luscombe, Vincent B.,Jenkins, Matthew T.,Rodriguez, Alice L.,Engers, Darren W.,Blobaum, Anna L.,Conn, P. Jeffrey,Niswender, Colleen M.,Lindsley, Craig W.
supporting information, p. 1690 - 1695 (2019/02/24)
Herein, we report the discovery of a new, orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu7) negative allosteric modulator (NAM) that achieves exposure in cerebral spinal fluid (CSF) 2.5× above the in vitro IC50 at minimum effective doses (MEDs) of 3 mg/kg in preclinical anxiety models.
